Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trial

[1]  A. Nanbo,et al.  Exploring indoor and outdoor dust as a potential tool for detection and monitoring of COVID-19 transmission , 2024, iScience.

[2]  N. Hoertel,et al.  Efficacy of Fluvoxamine in Outpatients With COVID-19: Understanding Conflicting Conclusions From 2 Recent Meta-Analyses of the Same Clinical Trials. , 2023, The Annals of pharmacotherapy.

[3]  A. Ginde,et al.  Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial. , 2023, JAMA.

[4]  Charin Modchang,et al.  Modeling vaccination strategies with limited early COVID-19 vaccine access in low- and middle-income countries: A case study of Thailand , 2023, Infectious Disease Modelling.

[5]  N. Hirankarn,et al.  The impact of non-synonymous mutations on miRNA binding sites within the SARS-CoV-2 NSP3 and NSP4 genes , 2023, Scientific reports.

[6]  M. Peluso,et al.  Serotonin reduction in post-acute sequelae of viral infection , 2023, Cell.

[7]  A. Nanbo,et al.  Tracing the new SARS-CoV-2 variant BA.2.86 in the community through wastewater surveillance in Bangkok, Thailand. , 2023, Lancet. Infectious Diseases (Print).

[8]  Songsak Tongchusak,et al.  Assessment of safety and intranasal neutralizing antibodies of HPMC-based human anti-SARS-CoV-2 IgG1 nasal spray in healthy volunteers , 2023, Scientific reports.

[9]  M. Rich,et al.  The STOP COVID 2 Study: Fluvoxamine vs Placebo for Outpatients With Symptomatic COVID-19, a Fully Remote Randomized Controlled Trial , 2023, Open forum infectious diseases.

[10]  D. Sano,et al.  Tracing the transmission of Mpox through wastewater surveillance in Southeast Asia. , 2023, Journal of travel medicine.

[11]  Kunihiko Hashimoto.  Detrimental effects of COVID-19 in the brain and therapeutic options for long COVID: The role of Epstein–Barr virus and the gut–brain axis , 2023, Molecular psychiatry.

[12]  D. Sano,et al.  COVID-19 monitoring with sparse sampling of sewered and non-sewered wastewater in urban and rural communities , 2023, iScience.

[13]  H. Zhao,et al.  Increased interleukin-6 is associated with long COVID-19: a systematic review and meta-analysis , 2023, Infectious Diseases of Poverty.

[14]  F. Jalali,et al.  Cyproheptadine Treatment of COVID-19-Induced Enteritis: Implications for Hyperinflammatory Phase Management , 2023, ACG Case Reports Journal.

[15]  T. Henrich,et al.  Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC) , 2023, eLife.

[16]  K. Hashimoto,et al.  Overview of the potential use of fluvoxamine for COVID-19 and long COVID , 2023, Discover Mental Health.

[17]  E. Topol,et al.  Long COVID: major findings, mechanisms and recommendations , 2023, Nature Reviews Microbiology.

[18]  Daniel Rayner,et al.  Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis , 2023, Clinical Microbiology and Infection.

[19]  P. Marcato,et al.  In Vitro Inhibition of SARS-CoV-2 Infection by Bromhexine hydrochloride , 2022, bioRxiv.

[20]  A. Comellas,et al.  Brain Fog and Fatigue following COVID-19 Infection: An Exploratory Study of Patient Experiences of Long COVID , 2022, International journal of environmental research and public health.

[21]  M. Shah,et al.  Paxlovid Associated with Decreased Hospitalization Rate Among Adults with COVID-19 — United States, April–September 2022 , 2022, American Journal of Transplantation.

[22]  Nathan A Hotaling,et al.  Assessing the effect of selective serotonin reuptake inhibitors in the prevention of post-acute sequelae of COVID-19 , 2022, medRxiv.

[23]  F. Jalali,et al.  Low α-Thrombin/GPIbα Interaction Is a Potential Contributor to Platelet Hyper-reactivity in COVID-19 Patients , 2022, Thrombosis and Haemostasis.

[24]  N. Hoertel,et al.  Antidepressant Use and Its Association with 28-Day Mortality in Inpatients with SARS-CoV-2: Support for the FIASMA Model against COVID-19 , 2022, European Psychiatry.

[25]  D. Sano,et al.  Multiple traces of monkeypox detected in non-sewered wastewater with sparse sampling from a densely populated metropolitan area in Asia , 2022, The Science of the total environment.

[26]  Lisa E. Gralinski,et al.  Understanding COVID-19-associated coagulopathy , 2022, Nature Reviews Immunology.

[27]  E. Lau,et al.  Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study , 2022, The Lancet Infectious Diseases.

[28]  C. Steves,et al.  Profiling post-COVID syndrome across different variants of SARS-CoV-2 , 2022, medRxiv.

[29]  R. Likić,et al.  Could Fluvoxamine Dose De-escalation Increase Treatment Compliance Without Sacrificing Efficacy in COVID-19 Patients? , 2022, Clinical Pharmacokinetics.

[30]  N. Gronich,et al.  Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  D. Sedding,et al.  The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19 , 2022, Cell Reports Medicine.

[32]  S. Rakhshanderou,et al.  The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis , 2022, medRxiv.

[33]  J. L. Bernal,et al.  Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study , 2022, Nature Communications.

[34]  M. Shen,et al.  Antiviral Efficacy of Molnupiravir for COVID-19 Treatment , 2022, Viruses.

[35]  D. Boulware,et al.  Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization , 2022, JAMA network open.

[36]  J. E. Tamayo,et al.  Effect of Bromhexine among COVID-19 Patients - A Meta-Anaylsis , 2022, Respiratory infections and bronchiectasis.

[37]  E. Mills,et al.  Evaluating COVID-19 vaccines in the real world , 2022, The Lancet.

[38]  A. Reiersen,et al.  Fluvoxamine for the treatment of COVID-19 , 2022, The Lancet Global Health.

[39]  Xiaoping Zhou,et al.  Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis , 2022, Annals of medicine.

[40]  L. Price,et al.  Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19 , 2022, JAMA network open.

[41]  Kevin M. Kallmes,et al.  Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials , 2022, BMC Infectious Diseases.

[42]  Zebin Zhao,et al.  Return to normal pre-COVID-19 life is delayed by inequitable vaccine allocation and SARS-CoV-2 variants , 2022, Epidemiology and Infection.

[43]  N. Andrews,et al.  Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England , 2022, Nature Medicine.

[44]  B. Hoen,et al.  Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2) , 2021, PloS one.

[45]  Brook K. Baker,et al.  Test and treat: a missing link in the global fight against COVID-19 , 2021, The Lancet Global Health.

[46]  Z. Al-Aly,et al.  Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status , 2021, Nature Communications.

[47]  H. de la Salle,et al.  Platelet FcγRIIA-induced serotonin release exacerbates the severity of transfusion-related acute lung injury in mice , 2021, Blood advances.

[48]  A. Abdulamir,et al.  A randomised controlled trial of effectiveness and safety of Niclosamide as add on therapy to the standard of care measures in COVID-19 management , 2021, Annals of Medicine and Surgery.

[49]  G. Guyatt,et al.  Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial , 2021, The Lancet Global Health.

[50]  N. Hoertel,et al.  Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms , 2021, Molecular Psychiatry.

[51]  P. Ounjai,et al.  Tracking COVID-19 with wastewater to understand asymptomatic transmission , 2021, International Journal of Infectious Diseases.

[52]  Sharat J. Vayttaden,et al.  Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19 , 2021, Frontiers in Pharmacology.

[53]  P. McIntyre,et al.  Serotonin-induced vascular permeability is mediated by transient receptor potential vanilloid 4 in the airways and upper gastrointestinal tract of mice , 2021, Laboratory Investigation.

[54]  K. Kunzelmann.  Getting hands on a drug for Covid-19: Inhaled and Intranasal Niclosamide , 2021, The Lancet Regional Health - Europe.

[55]  A. Konradi,et al.  Bromhexine Hydrochloride Prophylaxis of COVID-19 for Medical Personnel: A Randomized Open-Label Study , 2021, medRxiv.

[56]  F. Jalali,et al.  COVID-19 Pathophysiology: Are Platelets and Serotonin Hiding in Plain Sight? , 2021, SSRN Electronic Journal.

[57]  D. Boulware,et al.  Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19 , 2021, Open forum infectious diseases.

[58]  F. Jalali,et al.  Platelet reactivity to thrombin differs between patients with COVID-19 and those with ARDS unrelated to COVID-19 , 2021, Blood Advances.

[59]  Ryan J. Low,et al.  Characterizing long COVID in an international cohort: 7 months of symptoms and their impact , 2020, EClinicalMedicine.

[60]  K. Armstrong,et al.  The Need for More and Better Testing for COVID-19. , 2020, JAMA.

[61]  J. Miller,et al.  Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. , 2020, JAMA.

[62]  Miguel Correa Marrero,et al.  Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms , 2020, Science.

[63]  Zhènglì Shí,et al.  Characteristics of SARS-CoV-2 and COVID-19 , 2020, Nature Reviews Microbiology.

[64]  A. Jacquet,et al.  NOD2-dependent BCG-induced trained immunity: A way to regulate innate responses to SARS-CoV2? , 2020, International Journal of Infectious Diseases.

[65]  O. Tsang,et al.  Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. , 2020, JAMA.

[66]  S. Safiri,et al.  Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial , 2020, BioImpacts : BI.

[67]  H. Krumholz,et al.  Extrapulmonary manifestations of COVID-19 , 2020, Nature Medicine.

[68]  Benjamin J. Polacco,et al.  A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.

[69]  G. Corsini,et al.  Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection , 2020, Pharmacological Research.

[70]  E. Lenze,et al.  "What Were You Before the War?" Repurposing Psychiatry During the COVID-19 Pandemic. , 2020, The Journal of clinical psychiatry.

[71]  Lei Liu,et al.  TEMPORARY REMOVAL: Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study , 2020 .

[72]  B. Nieswandt,et al.  Platelets release pathogenic serotonin and return to circulation after immune complex-mediated sequestration , 2018, Proceedings of the National Academy of Sciences.

[73]  Candace S. Brown,et al.  Management of SSRI-Induced Sexual Dysfunction , 1998, The Annals of pharmacotherapy.

[74]  Harry Joe,et al.  A remark on algorithm 643: FEXACT: an algorithm for performing Fisher's exact test in r x c contingency tables , 1993, TOMS.

[75]  Nitin R. Patel,et al.  ALGORITHM 643: FEXACT: a FORTRAN subroutine for Fisher's exact test on unordered r×c contingency tables , 1986, TOMS.

[76]  R. Vardanyan,et al.  16 – Antihistamine Drugs , 2006 .

[77]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .

[78]  G. Dobos,et al.  Review Article a Systematic Review and Meta-analysis Estimating the Expected Dropout Rates in Randomized Controlled Trials on Yoga Interventions , 2022 .